Overview
SS-31, also called elamipretide, is a peptide made of four amino acids. It binds cardiolipin, a fat in the inner membrane of mitochondria, the structures that produce energy inside cells.
Its prescription form, Forzinity, is FDA-approved to improve muscle strength in people with Barth syndrome who weigh at least 30 kilograms.
What is it being studied for?
The approved use is Barth syndrome, a rare inherited disorder that weakens muscle and the heart. Research has also covered primary mitochondrial myopathy, heart failure, and kidney injury.
Cardiolipin helps maintain the mitochondrial membrane and supports energy production. In Barth syndrome, the body cannot process cardiolipin normally.
What has research found?
In the initial placebo-controlled Barth syndrome study, elamipretide did not improve walking distance or fatigue more than placebo.
Forzinity’s accelerated approval was based on improved knee muscle strength during extended treatment in people with Barth syndrome. A follow-up trial must confirm the benefit to patients.
In animal studies, elamipretide improved mitochondrial function after an interruption in blood supply.
FDA status and development history
The FDA granted Forzinity accelerated approval in September 2025 for Barth syndrome in patients weighing at least 30 kilograms. It is not approved for other conditions.